Indegene IPO review 2024 – GMP, Financials And More

Indegene IPO  is coming up with its IPO will be open for subscription on may 06, 2024.This article will analyze the review ,strengths and weaknesses of the indegene IPO



Indegene IPO Review – Company Overview


Indegene Limited is a digital commercialization company in the global life sciences sector. Serving emerging biotech and pharmaceutical firms, it offers comprehensive solutions in R&D, medical, regulatory, and commercial operations.  Notably, 19 of the top 20 global biopharmaceutical companies are among its clients.




The company’s services can be divided into following categories:

  • Enterprise Commercial Solutions
  • Omnichannel Activation
  • Enterprise Medical Solutions
  • Enterprise Clinical Solutions and consultancy services

The subsidiary of the company, DT Associates Limited, provides consulting services under the “DT Consulting” brand. It helps life sciences companies manage their digital transformation efforts to ensure continued success in customer experience.

The company received the Platinum Level award at the 2023 Healthy Workplace Conference and Awards, a recognition given by Arogya World India Trust in partnership with the Public Health Foundation of India.

As of December 31, 2023, the company had 65 clients actively engaged with its services.

As of December 31, 2023, the company employed 5,181 people worldwide. Of these, 4,461 are based in India, 530 work in North America, 105 in Europe, 73 in China, and 12 in other regions.


About the Industry


The life sciences industry comprises entities engaged in the research, development, and manufacturing and marketing of drugs and medical devices.

 The two main segments within this industry are the biopharmaceutical and medical devices segments:

  • Biopharmaceutical. This segment comprises companies that discover, develop, manufacture, and sell drugs (chemical and biological-based) to cure, vaccinate, or alleviate symptoms of medical conditions or diseases.
  • Medical devices. This segment comprises companies involved in the research, development, production, and sale of systems and devices of medical applications, i.e., to treat or diagnose diseases or medical conditions.

 The combined sales of the biopharmaceutical and medical devices segments was estimated at ₹138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceuticals constituting 69% or ₹95.4 trillion (US$1.2 trillion). By 2026, the combined sales of the biopharmaceutical and medical devices segments are expected to reach ₹163.5 trillion (US$2.1 trillion) with biopharmaceuticals constituting 69% or ₹113 trillion (US$1.4 trillion). 


Indegene Financial 


  FY 2022 FY 2023 9M FY 2024
Revenue 1,664.61 2,306.13 1,916.61
Expenses 1,417.10 2,001.05 1,644.64
Net income 162.82 266.10 241.90
Margin (%) 9.78 11.54 12.62

Figures in INR Crores

Indegene IPO Peer Comparison


There are no listed companies in India and globally that engage in a business that is similar to that of Indegene Company.


Strengths Of The Company 


  • Domain expertise in healthcare.
  • Robust digital capabilities and in-house developed technology portfolio.
  • Track record of establishing long-standing client relationships.
  • Global delivery model.
  • Experienced management and motivated talent pool supported by marquee investors.
  • Track record of creating value through acquisitions.


Object Of The Issue


  • Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc.;
  • Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.; and
  • General corporate purposes and inorganic growth.


ALSO READ – fundamental-analysis-of-maruti-suzuki


Indegene IPO GMP 


Not updated


Indegene IPO – key Details


IPO Opening Date 06 May 2024
IPO Closing Date 08 May 2024
Issue Type Book Built Issue IPO
Issue Size 4,07,46,891 Shares Worth ₹1,841.76 Crore

Fresh Issue: 1,68,14,159 Shares Worth ₹760.00 Crore

Offer For Sale: 2,39,32,732 Shares Worth ₹1,081.76 Crore

Face Value ₹2 per equity share
IPO Price ₹430 – ₹452
Market Lot 33 Shares
Min Order 33 Shares (1 Lot)
Employee Discount ₹30
Listing At BSE, NSE
Register Link Intime India Private Ltd
QIB Shares Offered 50%
NII (HNI) Shares Offered 15%
Retail Shares Offered 35%

Indegene IPO – Allotment Status


Indegene IPO allotment status will be available on Link Intime’s website. Click on Link Intime IPO weblink to get allotment status.





Disclaimer-The content presented here is intended solely for analytical and educational purposes. If you consider investing, it is strongly advised to conduct your own thorough research. We do not endorse or recommend any specific stocks or initial public offerings (IPOs)


Leave a Comment